Specialized Migraine Treatment Solutions for Unique Operational Environments
Legal Citation
Summary of the Inventive Concept
The present disclosure relates to novel, specialized migraine treatment solutions tailored to specific, niche operational environments, including high-altitude settings, patients with motion sickness or cochlear implants, and remote wilderness areas.
Background and Problem Solved
Migraine is a prevalent and debilitating condition requiring effective treatments. The original patent addressed the acute treatment of migraine with or without aura. However, there exists an unmet need for treatments adapted to specific, challenging environments. The present inventive concept addresses this limitation by providing specialized solutions for high-security needs, disaster relief, or extreme weather conditions.
Detailed Description of the Inventive Concept
The inventive concept comprises a system and method for treating acute migraine in unique operational environments. Claim 1 describes a system for treating acute migraine in a high-altitude environment, wherein the calcitonin gene-related peptide receptor antagonist is formulated to account for decreased oxygen levels. Claim 2 details a method for treating acute migraine in a patient with a history of motion sickness, comprising orally administering a pharmaceutical composition comprising ubrogepant and an anti-emetic agent. Claim 3 outlines a system for treating acute migraine in a patient with a cochlear implant, comprising administering a calcitonin gene-related peptide receptor antagonist in a formulation that minimizes electromagnetic interference with the implant. Claim 4 describes a method for treating acute migraine in a patient undergoing chemotherapy, comprising orally administering a pharmaceutical composition comprising ubrogepant and an anti-nausea agent. Claim 5 details a system for treating acute migraine in a patient in a remote wilderness area, comprising a portable, self-contained unit for administering a calcitonin gene-related peptide receptor antagonist, including a GPS tracking device and a communication device for emergency situations.
Novelty and Inventive Step
The inventive concept's novelty lies in its adaptation of migraine treatment solutions to specific, niche operational environments. The inventive step resides in the formulation and administration of calcitonin gene-related peptide receptor antagonists and pharmaceutical compositions tailored to these unique environments, ensuring effective treatment while mitigating environmental and individual challenges.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include adapting the system and method for treating acute migraine in other specialized environments, such as high-security facilities, disaster relief zones, or extreme weather conditions. Variations could also include different formulations of calcitonin gene-related peptide receptor antagonists or pharmaceutical compositions, as well as alternative administration methods.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the migraine treatment market. Target industries include high-altitude tourism, aerospace, and military operations, as well as healthcare providers catering to patients with unique needs, such as those with motion sickness or cochlear implants.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical treatment of neurological conditions, specifically migraine management, with expertise in pharmacokinetics, drug formulation, and patient-specific treatment protocols
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or clinical pharmacologist with advanced training in neuropharmacology, experienced in developing targeted drug delivery systems, understanding patient-specific treatment variations, and adapting pharmaceutical interventions to unique physiological conditions
Obviousness Rationale
A PHOSITA would recognize that the PTD represents predictable extensions of the source patent's core technology by applying known pharmaceutical adaptation techniques to specific patient environments. The variations demonstrate standard problem-solving approaches in drug delivery, utilizing well-established pharmaceutical engineering principles to modify ubrogepant's administration for unique clinical scenarios. These adaptations represent routine optimization strategies that would be immediately apparent to a skilled practitioner familiar with migraine treatment protocols.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,542 |
|---|---|
| Title | Treatment of migraine |
| Assignee(s) | Allergan Pharmaceuticals International Limited |